Vanda Pharmaceuticals (VNDA) Given Daily Media Impact Rating of 0.23
News headlines about Vanda Pharmaceuticals (NASDAQ:VNDA) have been trending somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Vanda Pharmaceuticals earned a daily sentiment score of 0.23 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.511962695045 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Shares of Vanda Pharmaceuticals (NASDAQ VNDA) traded up $0.30 during trading on Monday, hitting $14.35. 1,483,400 shares of the stock traded hands, compared to its average volume of 551,877. Vanda Pharmaceuticals has a 1 year low of $11.90 and a 1 year high of $18.99.
Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). The firm had revenue of $41.30 million for the quarter, compared to analysts’ expectations of $43.90 million. Vanda Pharmaceuticals had a negative net margin of 9.01% and a negative return on equity of 10.99%. The business’s revenue was up 7.3% on a year-over-year basis. During the same quarter last year, the business earned ($0.01) earnings per share. research analysts forecast that Vanda Pharmaceuticals will post -0.42 EPS for the current fiscal year.
A number of equities research analysts have recently issued reports on VNDA shares. Zacks Investment Research downgraded shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, October 26th. Jefferies Group reissued a “buy” rating and issued a $21.00 price target on shares of Vanda Pharmaceuticals in a report on Tuesday, August 29th. Piper Jaffray Companies raised their target price on shares of Vanda Pharmaceuticals from $23.00 to $26.00 and gave the company an “overweight” rating in a research note on Thursday, September 14th. Oppenheimer set a $26.00 target price on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, October 29th. Finally, BidaskClub raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 22nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. Vanda Pharmaceuticals has a consensus rating of “Buy” and an average price target of $21.50.
TRADEMARK VIOLATION WARNING: “Vanda Pharmaceuticals (VNDA) Given Daily Media Impact Rating of 0.23” was first published by Watch List News and is owned by of Watch List News. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/vanda-pharmaceuticals-vnda-given-daily-media-impact-rating-of-0-23/1771452.html.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.